When surveyed by the agency on November 12, Yuheng Pharmaceutical said that the company's core products have basically entered the collection catalogue of national/provincial alliances. There is a certain cycle of collection, and sales of collected products are expected to remain stable or grow in the future. Currently, the impact of the collection policy on the company's overall performance is relatively limited.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.